Journal
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
Volume 34, Issue 6, Pages 721-729Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/00952990802308262
Keywords
aripiprazole; cocaine; pharmacotherapy; physiological effects; subjective effects
Categories
Funding
- NCRR NIH HHS [M01 RR002602-225142, M01 RR002602, M01 RR02602] Funding Source: Medline
- NIDA NIH HHS [R01 DA020429, R01 DA020429-04, K01 DA018772, R01 DA 020429, K01 DA018772-04] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002602] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [K01DA018772, R01DA020429] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Objectives: This experiment determined the safety and tolerability of intranasal cocaine during aripiprazole maintenance. Methods: Six cocaine-dependent human subjects were maintained on aripiprazole (15 mg) and placebo for 10 days in counterbalanced order prior to assessing the physiological and subject-rated effects of intranasal cocaine. Results: Intranasal cocaine produced prototypical stimulant-like effects (e.g., increased blood pressure and heart rate, increased subject ratings of Like Drug and Stimulated), and aripiprazole enhanced these effects on several measures. Conclusions: Aripiprazole (15 mg/day) is safe and tolerable when combined with cocaine; however, the usefulness of aripiprazole as a treatment for cocaine-use disorders remains to be determined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available